Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis

Real‐world effectiveness and safety of direct‐acting antivirals in patients with liver cirrhosis and history of hepatic decompensation: Epi‐Ter2 Study

(2021) Aleksandra Berkan‐Kawińska et al.   LIVER INTERNATIONAL

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus

(2021) Takashi Kumada et al.   Infectious Diseases and Therapy

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation

(2021) Jessie Torgersen et al.   JOURNAL OF HEPATOLOGY

DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort

(2020) Elizabeth C. Verna et al.   JOURNAL OF HEPATOLOGY

Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

(2020) Sabela Lens et al.   JOURNAL OF HEPATOLOGY

Hepatic benefits of HCV cure

(2020) Vincenza Calvaruso et al.   JOURNAL OF HEPATOLOGY

In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent

(2020) Therese Bittermann et al.   Clinical Gastroenterology and Hepatology

Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study

(2020) Yuki Tahata et al.   JOURNAL OF GASTROENTEROLOGY

Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

(2020) Lisette A.P. Krassenburg et al.   JOURNAL OF HEPATOLOGY

Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?

(2019) Amr Shaaban Hanafy et al.   Hepatology International

Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation

(2019) Lisa Sandmann et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin

(2019) Ezequiel Ridruejo et al.   JOURNAL OF VIRAL HEPATITIS

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis

(2019) Ira M. Jacobson et al.   Clinical and Translational Gastroenterology

Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil

(2019) Cirley Maria de Oliveira Lobato et al.   Annals of Hepatology

Efficacy of direct‐acting antivirals: UK real‐world data from a well‐characterised predominantly cirrhotic HCV cohort

(2019) Lucia Macken et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis

(2018) Joseph K. Lim et al.   Clinical Gastroenterology and Hepatology

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

(2018) Omar El-Sherif et al.   GASTROENTEROLOGY

Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies

(2018) Matthew D. F. McInnes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens

(2018) A. Mangia et al.   JOURNAL OF HEPATOLOGY

Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry

(2018) Luca Saverio Belli et al.   JOURNAL OF HEPATOLOGY

Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4–infected patients with advanced liver fibrosis and decompensated cirrhosis

(2018) Faisal M. Sanai et al.   JOURNAL OF INFECTION

One Thousand Pediatric Liver Transplants During Thirty Years: Lessons Learned

(2018) Robert S. Venick et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults

(2018) Chiara Mazzarelli et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Efficacy of generic oral directly acting agents in patients with hepatitis C virus infection

(2018) S. Gupta et al.   JOURNAL OF VIRAL HEPATITIS

Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

(2018) Niels Steinebrunner et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis

(2018) Mohamed Essa et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)

(2018) Ivan Gentile et al.   Hepatology International

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

(2017) Pierre Nahon et al.   GASTROENTEROLOGY

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

(2017) Carlos Fernández Carrillo et al.   HEPATOLOGY

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

(2017) Jose Luis Calleja et al.   JOURNAL OF HEPATOLOGY

Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation

(2017) Juan Manuel Pascasio et al.   JOURNAL OF HEPATOLOGY

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension

(2017) N. Afdhal et al.   JOURNAL OF VIRAL HEPATITIS

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

(2017) Tarik Asselah et al.   LIVER INTERNATIONAL

Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation

(2017) Amber O. Molnar et al.   SEMINARS IN DIALYSIS

Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice

(2016) L. I. Backus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis

(2016) Raoel Maan et al.   Clinical Gastroenterology and Hepatology

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

(2016) Norah A. Terrault et al.   GASTROENTEROLOGY

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

(2016) Tania M Welzel et al.   GUT

Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy

(2016) Jennifer A. Flemming et al.   HEPATOLOGY

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

The Real-World Israeli Experience of Treating Chronic Hepatitis C, Genotype 1 Patients with Advanced Fibrosis with Paritaprevir/Ritonavir/Ombitasvir, Dasabuvir with or without Ribavirin: A Large Multi-Center Cohort

(2016) E. Zuckerman et al.   JOURNAL OF HEPATOLOGY

Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study

(2016) Luca Saverio Belli et al.   JOURNAL OF HEPATOLOGY

Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension

(2016) Mattias Mandorfer et al.   JOURNAL OF HEPATOLOGY

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis

(2016) Michelle C.M. Cheung et al.   JOURNAL OF HEPATOLOGY

Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era

(2016) S. A. McDonald et al.   JOURNAL OF VIRAL HEPATITIS

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease

(2016) E. Lawitz et al.   JOURNAL OF VIRAL HEPATITIS

Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

(2016) S. Alonso et al.   JOURNAL OF VIRAL HEPATITIS

Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index

(2016) Jacqueline A. Bachofner et al.   LIVER INTERNATIONAL

Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis

(2016) Apurva A. Modi et al.   LIVER TRANSPLANTATION

Abstracts

(2016)   TRANSPLANTATION

Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies

(2015) K. Deterding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin

(2015) Mitchell L Shiffman et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

(2015) Varun Saxena et al.   HEPATOLOGY

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

(2014) Eric Lawitz et al.   LANCET

Treatment of chronic hepatitis C in Asia: When East meets West

(2009) Ming-Lung Yu et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY